Meeting
2018 ASCO Annual Meeting
The influence of surgical excision on survival in high-risk neuroblastoma revisited after introduction of ch14.18/CHO immunotherapy in the HR-NBL1/SIOPEN trial.
Authors
Keith Holmes
St George's Hospital, London, United Kingdom
Keith Holmes , Ulrike Poetschger , Sabine Sarnacki , Tom Monclair , Giovanni Cecchetto , Javier Gomez Chacon , Jacob Stenman , Jean-Marc Joseph , Roberto Luksch , Victoria Castel , Shifra Ash , Vassilios Papadakis , Josef Malis , Walentyna Balwierz , Cormac Owens , Holger N. Lode , Tom Boterberg , Dominique Valteau Couanet , Andrew DJ Pearson , Ruth Lydia Ladenstein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT01704716
Citation
J Clin Oncol 36, 2018 (suppl; abstr 10521)
DOI
10.1200/JCO.2018.36.15_suppl.10521
Abstract #
10521
Poster Bd #
194
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Matched external control analysis of event-free survival (EFS) in patients with high-risk neuroblastoma (HRNB) receiving eflornithine (DFMO) maintenance.
First Author: Javier E. Oesterheld
Poster
2016 ASCO Annual Meeting
Prognostic factors in stage 4 neuroblastoma treated with busulphan-melphalan: Report from the European HR-NBL1/Siopen trial.
First Author: Ruth Ladenstein
Poster
2014 ASCO Annual Meeting
Immunotherapy (IT) with ch14.18/CHO for high-risk neuroblastoma: First results from the randomised HR-NBL1/SIOPEN trial.
First Author: Ruth L Ladenstein
Poster
2021 ASCO Annual Meeting
Racial and ethnic disparities in risk and survival in children with neuroblastoma: An updated analysis.
First Author: Caileigh Pudela